Compare MRAM & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | ENTA |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | 87 | 120 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.4M | 486.3M |
| IPO Year | 2016 | 2013 |
| Metric | MRAM | ENTA |
|---|---|---|
| Price | $9.34 | $16.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.50 | ★ $20.40 |
| AVG Volume (30 Days) | 153.0K | ★ 367.2K |
| Earning Date | 11-05-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $53,642,000.00 | ★ $65,324,000.00 |
| Revenue This Year | $11.00 | $0.99 |
| Revenue Next Year | $9.39 | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.34 | $4.09 |
| 52 Week High | $12.27 | $17.05 |
| Indicator | MRAM | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 71.71 |
| Support Level | $8.38 | $14.07 |
| Resistance Level | $9.55 | $17.05 |
| Average True Range (ATR) | 0.42 | 0.91 |
| MACD | 0.07 | 0.12 |
| Stochastic Oscillator | 69.21 | 89.70 |
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.